business
An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
Read full story on MarketWatch → More top storiesAlso covered by
Investing.com
Novartis’ experimental prostate cancer drug shows promise
CNBC
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
Bloomberg Markets
Akeso To Boost Manufacturing Of Cancer Drug
NPR News
Experimental pill promises new hope for deadly pancreatic cancer
Aggregated and edited by the Scoop newsroom. We surface news from MarketWatch alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop